Medicine withdrawn
On 25 October, 2021, the license for dapagliflozin (Forxiga) 5mg, in adults for the treatment of insufficiently controlled type 1 diabetes mellitus, as an adjunct to insulin in patients with BMI ≥27kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy, was withdrawn.
Medicine details
- Medicine name:
- dapagliflozin (Forxiga)
- SMC ID:
- SMC2185
- Indication:
In adults for the treatment of insufficiently controlled T1DM as an adjunct to insulin in patients with BMI ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Withdrawn
- Date advice published
- 09 September 2019
On 25 October, 2021, AstraZeneca published a statement advising dapagliflozin (Forxiga) 5mg is no longer authorised for the treatment of patients with type 1 diabetes mellitus and therefore should not be used in this population.
In line with SMC process, the SMC advice has been removed from the website.